{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:00:18Z","timestamp":1785308418662,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"\n Background<\/jats:title>\n Pediatric inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), may affect health-related quality of life (HRQoL) beyond clinical disease activity alone. Although biologic therapy has improved disease control, its relationship with disease-specific HRQoL, generic HRQoL, and family functioning in real-world cohort of children with IBD remains insufficiently defined. This study aimed to assess HRQoL and family functioning in children with IBD according to treatment modality and disease type.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This single-center, cross-sectional study enrolled children aged 8\u201317 years with confirmed IBD at Sechenov University, between 2024 and 2026. Participants were stratified by treatment modality into those receiving biologic therapy in combination with conventional therapy and those receiving conventional therapy alone, and by disease type into CD and UC groups. Disease-specific HRQoL was assessed using IMPACT-III, generic HRQoL using the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), and family functioning using the PedsQL Family Impact Module (PedsQL FIM). Nonparametric methods were used, and correlations were assessed using Spearman's correlation coefficient.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The cohort comprised 105 children with IBD, including 59 with CD and 46 with UC. Thirty-eight children received biologic therapy in combination with conventional therapy, and 67 received conventional therapy alone. No statistically significant differences were detected between treatment groups in total IMPACT-III, PedsQL, or PedsQL FIM scores. Similarly, HRQoL and family functioning did not differ significantly between children with CD and UC. Across treatment groups, social functioning had the highest scores, whereas emotional functioning was consistently among the lowest-scoring domains. In the PedsQL FIM, family relationships had the highest scores and worry had the lowest scores. Significant positive correlations were identified between IMPACT-III and PedsQL total scores (\n \u03c1<\/jats:italic>\n \u2009=\u20090.599,\n p<\/jats:italic>\n \u2009&lt;\u20090.001), between IMPACT-III and PedsQL FIM total scores (\n \u03c1<\/jats:italic>\n \u2009=\u20090.291,\n p<\/jats:italic>\n \u2009=\u20090.003), and between PedsQL and PedsQL FIM total scores (\n \u03c1<\/jats:italic>\n \u2009=\u20090.333,\n p<\/jats:italic>\n \u2009&lt;\u20090.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this Russian cohort of children with IBD, HRQoL and family functioning were similar across treatment groups and disease types. Emotional functioning and parental worry remained key challenges, highlighting the importance of routine HRQoL assessment and family-centered support.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fped.2026.1908855","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:02:25Z","timestamp":1785304945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-Related quality of life in Russian children with inflammatory bowel disease is comparable across disease types and treatment modalities"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuen Kai","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre V.","family":"Gorelov","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]},{"name":"Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Yablokova","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]},{"name":"Research Clinical Institute of Childhood, Ministry of Health of Moscow Region","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Borisova","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Krikun","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana B.","family":"Krutikhina","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Ozerskaia","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Kudryashova","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina V.","family":"Polyanskaya","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana N.","family":"Chebysheva","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Savvateeva","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey M.","family":"Savvateev","sequence":"additional","affiliation":[{"name":"Department of Children's Diseases, Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3238\/arztebl.2016.0072","article-title":"Inflammatory bowel disease: crohn\u2019s disease and ulcerative colitis","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","article-title":"Inflammatory bowel disease","volume":"50","author":"Bruner","year":"2023","journal-title":"Prim Care Clin Off Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e29282","DOI":"10.7759\/cureus.29282","article-title":"Health-Related quality of life in pediatric inflammatory bowel disease patients: a narrative review","volume":"14","author":"Ahmed","year":"2022","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.crohns.2012.12.010","article-title":"The IMPACT-III (HR) questionnaire: a valid measure of health-related quality of life in Croatian children with inflammatory bowel disease","volume":"7","author":"Abdovic","year":"2013","journal-title":"J Crohns Colitis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MPG.0b013e3182662233","article-title":"Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines","volume":"55","author":"Turner","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3748\/wjg.v23.i6.1067","article-title":"Disease impact on the quality of life of children with inflammatory bowel disease","volume":"23","author":"Chouliaras","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11136-011-9853-3","article-title":"Maternal, paternal, and family health-related quality of life in the context of pediatric inflammatory bowel disease","volume":"20","author":"Kunz","year":"2011","journal-title":"Qual Life Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jpepsy\/jsp120","article-title":"A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease","volume":"35","author":"Greenley","year":"2010","journal-title":"J Pediatr Psychol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.31550\/1727-2378-2020-19-10-27-32","article-title":"Quality of life of children with crohn\u2019s disease as a potential criterion for monitoring disease activity","volume":"19","author":"Tagirova","year":"2020","journal-title":"Doctor.Ru"},{"key":"B11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.crohns.2013.11.025","article-title":"Validation of the IMPACT-III quality of life questionnaire in Swiss children with inflammatory bowel disease","volume":"8","author":"Werner","year":"2014","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/apa.14119","article-title":"IMPACT-III is a valid and reliable questionnaire for assessing health-related quality of life in Swedish children with inflammatory bowel disease","volume":"107","author":"Uggla","year":"2018","journal-title":"Acta Paediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/MPG.0000000000003716","article-title":"Validation of the IMPACT-III questionnaire in French children with inflammatory bowel disease","volume":"76","author":"Vanhelst","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/jpc.16130","article-title":"Quality of life in Malaysian children with inflammatory bowel disease: an understudied population","volume":"58","author":"Lee","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"B15","year":""},{"key":"B16","year":""},{"key":"B17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/164_2019_255","article-title":"Therapeutics for inflammatory bowel diseases in children and adolescents: a focus on biologics and an individualized treatment paradigm.","volume-title":"Pediatric Pharmacotherapy. Handbook of Experimental Pharmacology","author":"Batra","year":"2019"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ibd\/izad277","article-title":"Pediatric IBD patients treated with infliximab and proactive drug monitoring benefit from early concomitant immunomodulatory therapy: a retrospective analysis of a 10-year real-life cohort","volume":"30","author":"Hoelz","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jpn3.12179","article-title":"Combination biologic therapy in pediatric inflammatory bowel disease: safety and efficacy over a minimum 12-month follow-up period","volume":"79","author":"Wlazlo","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.20953\/1727-5784-2021-3-14-25","article-title":"Therapeutic drug monitoring of Adalimumab in inflammatory bowel disease in children","volume":"19","author":"Illarionov","year":"2021","journal-title":"Vopr Det Dietol"},{"key":"B21","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00005176-200210000-00018","article-title":"The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease","volume":"35","author":"Otley","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/MPG.0000000000002824","article-title":"A new domain structure for the IMPACT-III health-related quality of life tool for pediatric inflammatory bowel disease","volume":"71","author":"Grant","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL\u2122 4.0: reliability and validity of the pediatric quality of life InventoryTM version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-7525-2-55","article-title":"The PedsQL\u2122 family impact module: preliminary reliability and validity","volume":"2","author":"Varni","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s11136-017-1513-9","article-title":"Changes in health-related quality of life over a 1-year follow-up period in children with inflammatory bowel disease","volume":"26","author":"Werner","year":"2017","journal-title":"Qual Life Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1908855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:02:26Z","timestamp":1785304946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1908855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":26,"alternative-id":["10.3389\/fped.2026.1908855"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1908855","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1908855"}}